TriSalus Life Sciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$52.4Mnext fiscal year
FY EPS (est.)
-$0.29next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly8.9MTarget: Revised FY 2026 Revenue Guidance of $54 million to $57 million
Gross Margin Quarterly8,620.0%Target: Mid-to-high 80s
Cash and Cash Equivalents Quarterly56.6MTarget: Sufficient cash runway to fully fund commercial expansion and pipeline development
Watch Items
- Commercial Adoption of TriNav SystemTrigger: Revenue growth falling below the revised FY 2026 guidance range of $54M to $57MAction: Re-evaluate sales force expansion strategy and commercial execution across interventional radiology accounts
- Clinical Trial Progress for NelitolimodTrigger: Delays in data completion for Phase 1 trials or initiation of PREDICTT trialAction: Assess clinical development timelines and explore strategic partnership opportunities
Research as of 19 Jun 2026